Evaluation of Prospectively Followed Adult Patients with Erythema Migrans Using the Beck Depression Inventory Second Edition

Published:December 15, 2018DOI:



      The Beck Depression Inventory (BDI-II) may be used to evaluate individuals for symptoms of depression.


      In a 1-year prospective study, 52 adult Lyme disease patients with erythema migrans and 104 matched control subjects were clinically assessed and completed the BDI-II at study entry and approximately 6 and 12 months later following antibiotic treatment.


      The mean BDI-II score was significantly higher at the baseline visit among Lyme disease patients compared with controls (P = .002), but no significant differences between the groups were observed at either the 6- or 12-month study visits. Over the course of the study, the mean BDI-II scores decreased an average of approximately 0.22 points per month (P < .0005) for Lyme disease patients, whereas the mean scores changed very little for controls (mean change = −0.02 per month, P = .50). The total number of somatic symptoms, of the 12 symptoms evaluated, strongly and directly correlated with the BDI-II scores at the baseline visit for the Lyme disease patients.


      The mean BDI-II scores of patients with early Lyme disease significantly exceeded that of matched controls at study entry, but by 6 months the values did not differ significantly. There was a good-to-excellent direct correlation between the BDI-II score and the total number of symptoms, suggesting that the BDI-II scores were reflecting somatic rather than affective depressive symptoms. When using the BDI-II as an assessment tool of patients with Lyme disease, infection-related somatic symptoms per se need to be considered in the interpretation of the results.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hinckley AF
        • Connally NP
        • Meek JI
        • et al.
        Lyme disease testing by large commercial laboratories in the United States.
        Clin Infect Dis. 2014; 59: 678-681
        • Nelson CA
        • Saha S
        • Kugeler KJ
        • et al.
        Incidence of clinician-diagnosed Lyme disease, United States, 2005-2010.
        Emerg Infect Dis. 2015; 21: 1625-1631
        • Sanchez E
        • Vannier E
        • Wormser GP
        • Hu LT
        Diagnosis, treatment and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: A review.
        JAMA. 2016; 315: 1767-1777
        • Wormser GP
        • Dattwyler RJ
        • Shapiro ED
        • et al.
        The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.
        Clin Infect Dis. 2006; 43: 1089-1134
        • Beck A
        • Steer R
        • Brown G
        Beck Depression Inventory Second Edition Manual.
        The Psychological Corporation, San Antonio1996
        • Osman A
        • Downs WR
        • Barrios FX
        • Kopper BA
        • Gutierrez PM
        • Chiros CE
        Factor structure and psychometric characteristics of the Beck Depression Inventory-II.
        J Psychopathol Behav Assess. 1997; 19: 359
        • Wormser GP
        • Sudhindra P
        • Lopez E
        • et al.
        Fatigue in patients with erythema migrans.
        Diagn Microbiol Infect Dis. 2016; 86: 322-326
        • Tibbles CD
        • Edlow JA.
        Does this patient have erythema migrans?.
        JAMA. 2007; 297: 2617-2627
        • Weitzner E
        • McKenna D
        • Nowakowski J
        • et al.
        Long-term assessment of post-treatment symptoms in patients with culture-confirmed early Lyme disease.
        Clin Infect Dis. 2015; 61: 1800-1806
        • Portney LG
        • Watkins MP
        Foundations of Clinical Research: Applications to Practice.
        3rd ed. Pearson Education, Inc., Upper Saddle River, NJ2009
        • Bechtold KT
        • Rebman AW
        • Crowder LA
        • Johnson-Greene D
        • Aucott JN
        Standardized symptom measurement of individuals with early Lyme disease over time.
        Arch Clin Neuropsychol. 2017; 32: 129-141
        • Patterson AL
        • Morasco BJ
        • Fuller BE
        • Indest DW
        • Loftis JM
        • Hauser P
        Screening for depression in patients with hepatitis C using the Beck Depression Inventory-II: do somatic symptoms compromise validity?.
        Gen Hosp Psychiatry. 2011; 33: 354-362
        • Zomer TP
        • Vermeeren YM
        • Landman GW
        • et al.
        Depressive symptoms in patients referred to a tertiary Lyme center: high prevalence in those without evidence of Lyme borreliosis.
        Clin Infect Dis. 2017; 65: 1689-1694
        • Whisman MA
        • Richardson ED
        Normative data on the Beck depression inventory-second edition (BDI-II) in college students.
        J Clin Psychol. 2015; 71: 898-907
        • Kessler RC
        • Birnbaum HG
        • Shahly V
        • et al.
        Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: results from the WHO World Mental Health Survey Initiative.
        Depress Anxiety. 2010; 27: 351-364